News | August 30, 2023
Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
Reiterates India’s commitment to the BRICS TB Research Network Initiative
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Subscribe To Our Newsletter & Stay Updated
